Identification of Protein Expression Changes in Hepatocellular Carcinoma through iTRAQ

Area of Science:

• Oncology
• Biochemistry
• Proteomics

Background:

• Hepatocellular carcinoma (HCC) presents a poor prognosis.
• Serum biomarkers are crucial for HCC diagnosis, monitoring, and malignancy prediction.
• Differential protein expression between HCC patients and controls can identify potential biomarkers.

Purpose of the Study:

• To identify novel serum protein biomarkers for hepatocellular carcinoma (HCC).
• To validate potential biomarkers for HCC diagnosis and prognosis.

Main Methods:

• Proteomic analysis using isobaric tags for relative and absolute quantitation (iTRAQ) on serum samples from HCC patients and controls.
• Enzyme-linked immunosorbent assay (ELISA) validation of candidate biomarkers.
• Analysis of gene expression data from The Cancer Genome Atlas (TCGA) dataset.

Main Results:

• Forty-one out of 260 measured serum proteins showed significant differential expression in HCC.
• Paraoxonase 1 (PON1) was identified as a downregulated protein.
• Validation confirmed PON1 downregulation in HCC serum, and TCGA data showed decreased PON1 expression in HCC tissues associated with poor survival.

Conclusions:

• Paraoxonase 1 (PON1) demonstrates potential as a diagnostic biomarker for hepatocellular carcinoma (HCC).
• Low PON1 expression is linked to poorer survival outcomes in HCC patients.